MSH 2IA
Alternative Names: MagSense® HER2 Imaging Agent; MSH-2IALatest Information Update: 21 Feb 2024
Price :
$50 *
At a glance
- Originator Imagion Biosystems
- Class Contrast media; Diagnostic agents; Diagnostic conjugates; Ferric compounds; Growth factors; Imaging agents; Oxides; Radiopharmaceutical diagnostics
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I HER2 positive breast cancer
Most Recent Events
- 13 Dec 2023 Imagion Biosystems announces intention to file an IND application with the US FDA in Q1 2024
- 13 Dec 2023 Efficacy and adverse events data from a phase-I IBI10103 trial in HER-2 positive breast cancer released byImagion Biosystems
- 13 Dec 2023 Imagion Biosystems completes a phase-I IBI10103 trial in HER-2 positive breast cancer in Australia (unspecified route) (Imagion Biosystems pipeline, December 2023) (ACTRN12621000126819)